Sabine Windhorst

Prof. Dr. Sabine Windhorst


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2018 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
JSJohanna Schiewek
Johanna Schiewek
USUdo Schumacher
Udo Schumacher
TLTobias Lange
Tobias Lange
SJSimon A. Joosse
Simon A. Joosse
HWHarriet Wikman-Kocher
Harriet Wikman-Kocher
SWSabine Windhorst
Sabine Windhorst

1 February 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SWSabine Windhorst
Sabine Windhorst
RFRalf Fliegert
Ralf Fliegert
CBChristine Blechner
Christine Blechner
KMKatharina Möllmann
Katharina Möllmann
ZHZara Hosseini
Zara Hosseini
GMGeorg W. Mayr
Georg W. Mayr
Cellular migration is an essential prerequisite for metastatic dissemination of cancer cells. This study demonstrates that the neuron/testis-specific F-actin-targeted inositol 1,4,5-trisphosphate 3-kinase-A (ITPKA) is ectopically expressed in different human tumor cell lines and during tumor progression in the metastatic tumor model Balb-neuT. High expression of ITPKA increases invasive migration in vitro and metastasis in a xenograft SCID mouse model. Mechanistic studies show that ITPKA promotes migration of tumor cells by two different mechanisms as follows: growth factor independently high levels of ITPKA induce the formation of large cellular protrusions by directly modulating the actin cytoskeleton. The F-actin binding activity of ITPKA stabilizes and bundles actin filaments and thus increases the levels of cellular F-actin. In growth factor-stimulated cells, the catalytically active domain enhances basal ITPKA-induced migration by activating store-operated calcium entry through production of inositol 1,3,4,5-tetrakisphosphate and subsequent inhibition of inositol phosphate 5-phosphatase. These two functional activities of ITPKA stimulating tumor cell migration place the enzyme among the potential targets of anti-metastatic therapy.

30 September 2020 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JAJulia Arnold
Julia Arnold
JSJuliana Schattschneider
Juliana Schattschneider
CBChristine Blechner
Christine Blechner
CKChristoph Krisp
Christoph Krisp
HSHartmut Schlüter
Hartmut Schlüter
SWSabine Windhorst
Sabine Windhorst
Background: The survival rate is poor in breast cancer patients with brain metastases. Thus, new concepts for therapeutic approaches are required. During metastasis, the cytoskeleton of cancer cells is highly dynamic and therefore cytoskeleton-associated proteins are interesting targets for tumour therapy. Methods: Screening for genes showing a significant correlation with brain metastasis formation was performed based on microarray data from breast cancer patients with long-term follow up information. Validation of the most interesting target was performed by MTT-, Scratch- and Transwell-assay. In addition, intracellular trafficking was analyzed by live-cell imaging for secretory vesicles, early endosomes and multiple vesicular bodies (MVB) generating extracellular vesicles (EVs). EVs were characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), Western blotting, mass spectrometry, and ingenuity pathway analysis (IPA). Effect of EVs on the blood-brain-barrier (BBB) was examined by incubating endothelial cells of the BBB (hCMEC/D3) with EVs, and permeability as well as adhesion of breast cancer cells were analyzed. Clinical data of a breast cancer cohort was evaluated by χ2-tests, Kaplan-Meier-Analysis, and log-rank tests while for experimental data Student’s T-test was performed. Results: Among those genes exhibiting a significant association with cerebral metastasis development, the only gene coding for a cytoskeleton-associated protein was Tubulin Tyrosine Ligase Like 4 (TTLL4). Overexpression of TTLL4 (TTLL4plus) in MDA-MB231 and MDA-MB468 breast cancer cells (TTLL4plus cells) significantly increased polyglutamylation of β-tubulin. Moreover, trafficking of secretory vesicles and MVBs was increased in TTLL4plus cells. EVs derived from TTLL4plus cells promote adhesion of MDA-MB231 and MDA-MB468 cells to hCMEC/D3 cells and increase permeability of hCMEC/D3 cell layer. Conclusions: These data suggest that TTLL4-mediated microtubule polyglutamylation alters exosome homeostasis by regulating trafficking of MVBs. The TTLL4plus-derived EVs may provide a pre-metastatic niche for breast cancer cells by manipulating endothelial cells of the BBB.

1 August 2017 in Biochemical Pharmacology
Verified
Journal Article
Closed access
SWSabine Windhorst
Sabine Windhorst
KSKai Song
Kai Song
AGAdi F. Gazdar
Adi F. Gazdar

1 March 2012 in Cellular Signalling
Verified
Journal Article
Closed access
SWSabine Windhorst
Sabine Windhorst
DMDaniel Minge
Daniel Minge
RBRobert Bähring
Robert Bähring
SHSvenja Hüser
Svenja Hüser
CSClaudia Schob
Claudia Schob
SKStefan Kindler
Stefan Kindler

17 September 2013 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
YLYuan‐Na Lin
Yuan‐Na Lin
JIJakob R. Izbicki
Jakob R. Izbicki
AKAlexandra König
Alexandra König
JHJens K. Habermann
Jens K. Habermann
CBChristine Blechner
Christine Blechner
SWSabine Windhorst
Sabine Windhorst
In most cases, metastatic colorectal cancer is not curable, thus new approaches are necessary to identify novel targets for colorectal cancer therapy. Actin‐binding‐proteins (ABPs) directly regulate motility of metastasising tumor cells, and for cortactin an association with colon cancer metastasis has been already shown. However, as its depletion only incompletely inhibits metastasis, additional, more suitable cellular targets have to be identified. Here we analyzed expression of the ABPs, DIAPH1, VASP, N‐WASP, and fascin in comparison with cortactin and found that, besides cortactin, DIAPH1 was expressed with the highest frequency (63%) in colorectal cancer. As well as cortactin, DIAPH1 was not detectable in normal colon tissue and expression of both proteins was positively correlated with metastasis of colorectal cancer. To analyse the mechanistic role of DIAPH1 for metastasis of colon carcinoma cells in comparison with cortactin, expression of the proteins was stably down‐regulated in the human colon carcinoma cell lines HT‐29, HROC‐24 and HCT‐116. Analysis of metastasis of colon carcinoma cells in SCID mice revealed that depletion of DIAPH1 reduced metastasis 60‐fold and depletion of cortactin 16‐fold as compared with control cells. Most likely the stronger effect of DIAPH1 depletion on colon cancer metastasis is due to the fact that in vitro knock down of DIAPH1 impaired all steps of metastasis; adhesion, invasion and migration while down‐regulation of cortactin only reduced adhesion and invasion. This very strong reducing effect of DIAPH1 depletion on colon carcinoma cell metastasis makes the protein a promising therapeutic target for individualized colorectal cancer therapy.